Favipiravir-induced fever in coronavirus disease 2019: A report of two cases

Favipiravir, an antiviral agent, is undergoing clinical trials for treating novel coronavirus disease 2019 (COVID-19). Here, we report two cases of COVID-19 with favipiravir-induced fever. In both cases, pyrexia was observed following the administration of favipiravir despite improvements in symptom...

Descripción completa

Detalles Bibliográficos
Autores principales: Takoi, Hiroyuki, Togashi, Yuki, Fujimori, Daiki, Kaizuka, Haruki, Otsuki, Shunsuke, Wada, Takuya, Takeuchi, Yoshikazu, Abe, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2020
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521433/
https://www.ncbi.nlm.nih.gov/pubmed/32992014
http://dx.doi.org/10.1016/j.ijid.2020.09.1450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7521433/
https://www.ncbi.nlm.nih.gov/pubmed/32992014
http://dx.doi.org/10.1016/j.ijid.2020.09.1450

Ejemplares similares